Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) EBT Margin (2017 - 2025)

UroGen Pharma's EBT Margin history spans 9 years, with the latest figure at 70.4% for Q4 2025.

  • For Q4 2025, EBT Margin rose 7152.0% year-over-year to 70.4%; the TTM value through Dec 2025 reached 139.74%, down 252.0%, while the annual FY2025 figure was 139.74%, 252.0% down from the prior year.
  • EBT Margin reached 70.4% in Q4 2025 per URGN's latest filing, up from 125.18% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 70.4% in Q4 2025 to a low of 346.49% in Q1 2021.
  • Average EBT Margin over 5 years is 166.02%, with a median of 158.31% recorded in 2022.
  • Peak YoY movement for EBT Margin: soared 822833bps in 2021, then tumbled -4933bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 168.88% in 2021, then rose by 8bps to 155.76% in 2022, then surged by 40bps to 94.19% in 2023, then tumbled by -51bps to 141.92% in 2024, then soared by 50bps to 70.4% in 2025.
  • Per Business Quant, the three most recent readings for URGN's EBT Margin are 70.4% (Q4 2025), 125.18% (Q3 2025), and 202.04% (Q2 2025).